Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AIRE - Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer - a Prospectively Randomized Phase IV Study

NCT05033769 is registered in ClinicalTrials.gov with Institut fuer Frauengesundheit as lead sponsor.

NCT NCT05033769
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05033769 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AIRE - Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer - a Prospectively Randomized Phase IV Study
Lead sponsor
Institut fuer Frauengesundheit
Phase
Phase 4
Overall status
Unknown status
Start date
March 11, 2021
Completion date
September 15, 2023
Enrollment
82 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer female, breast cancer metastatic, neoplasm, breast